Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
US-2021000816-A1 · Jan 7, 2021 · US
This page is not indexed by search engines while we improve data quality.
Patent family 54545079
This patent family groups 2 related publications across US. Members often share priority claims or equivalent filings in different countries.
| Field | Value |
|---|---|
| Family ID | 54545079 |
| Family type | — |
| Earliest priority | Oct 27, 2014 |
| First filing country | US |
| Member publications | 2 |
| Countries | US |
| Representative publication | US2021000816A1 — Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |
Representative publication
Best representative member for this family based on priority and filing country.
US2021000816A1 — Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer (published Jan 7, 2021)
Member publications
Related publications in this family.